The number of companies shrank, but the profit rose from RON1.1 billion in 2023 to RON1.7 billion last year, generated by the entire pharmaceutical industry in the country.
One drug manufacturer – Gedeon Richter, the Hungary-based group with a factory in Targu-Mures, stands out in particular by profit growth, almost 10 times in one year.
At the end of 2022, Gedeon sold its retail (94 pharmacies) and drug distribution business (Pharmapharm) to the Dr. Max group, active in the same pharmaceutical market.
In terms of employees, local production employs 9,800 people, with major manufacturers complaining of labor shortages in the sector.
The data were analyzed by ZF based on information from the Bridge to Information platform and include companies that published their 2024 financial results and are active in the drug manufacturing business. The activities considered were ‘Manufacture of pharmaceutical preparations’ (NACE 2120) and ‘Manufacture of basic pharmaceutical products’ (NACE 2110).
In recent years, major drug manufacturers in Romania have come up with investment projects, portfolio developments, new factories built from scratch.
However, as a result of the lack of a strategy of the authorities to support local production, the market remains dominated by imports.
(English version by Loredana Fratila-Cristescu)